HK1138188A1 - Solid preparation comprising alogliptin and pioglitazone - Google Patents

Solid preparation comprising alogliptin and pioglitazone

Info

Publication number
HK1138188A1
HK1138188A1 HK10103605.9A HK10103605A HK1138188A1 HK 1138188 A1 HK1138188 A1 HK 1138188A1 HK 10103605 A HK10103605 A HK 10103605A HK 1138188 A1 HK1138188 A1 HK 1138188A1
Authority
HK
Hong Kong
Prior art keywords
alogliptin
pioglitazone
solid preparation
preparation
solid
Prior art date
Application number
HK10103605.9A
Other languages
English (en)
Inventor
Kenji Nakamura
Kenichiro Kiyoshima
Junya Nomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1138188(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HK1138188A1 publication Critical patent/HK1138188A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10103605.9A 2007-02-01 2010-04-13 Solid preparation comprising alogliptin and pioglitazone HK1138188A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01
PCT/JP2008/051900 WO2008093882A1 (en) 2007-02-01 2008-01-30 Solid preparation comprising alogliptin and pioglitazone

Publications (1)

Publication Number Publication Date
HK1138188A1 true HK1138188A1 (en) 2010-08-20

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103605.9A HK1138188A1 (en) 2007-02-01 2010-04-13 Solid preparation comprising alogliptin and pioglitazone

Country Status (39)

Country Link
US (1) US8637079B2 (ko)
EP (1) EP2107905B1 (ko)
JP (1) JP5284968B2 (ko)
KR (1) KR101486091B1 (ko)
CN (1) CN101646420B (ko)
AR (1) AR065097A1 (ko)
AT (1) ATE488227T1 (ko)
AU (1) AU2008211981B2 (ko)
BR (1) BRPI0807453B8 (ko)
CA (1) CA2677201C (ko)
CL (1) CL2008000279A1 (ko)
CR (1) CR10992A (ko)
CY (1) CY1111264T1 (ko)
DE (1) DE602008003522D1 (ko)
DK (1) DK2107905T3 (ko)
DO (1) DOP2009000195A (ko)
EA (1) EA015180B1 (ko)
EC (1) ECSP099608A (ko)
ES (1) ES2354397T3 (ko)
GE (1) GEP20125410B (ko)
HK (1) HK1138188A1 (ko)
HR (1) HRP20110094T8 (ko)
IL (1) IL200108A (ko)
JO (1) JO2650B1 (ko)
MA (1) MA31169B1 (ko)
ME (1) ME01239B (ko)
MX (1) MX2009008100A (ko)
MY (1) MY147596A (ko)
NZ (1) NZ579008A (ko)
PE (1) PE20081663A1 (ko)
PL (1) PL2107905T3 (ko)
PT (1) PT2107905E (ko)
RS (1) RS51592B (ko)
SI (1) SI2107905T1 (ko)
TN (1) TN2009000317A1 (ko)
TW (2) TWI453041B (ko)
UA (1) UA95828C2 (ko)
WO (1) WO2008093882A1 (ko)
ZA (1) ZA200905621B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101536786B1 (ko) 2007-07-19 2015-07-14 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP3626238A1 (en) 2008-08-15 2020-03-25 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
AR073380A1 (es) * 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
UY32441A (es) 2009-02-13 2010-09-30 Boehringer Ingelheim Int Composicion farmaceutica, metodos de tratamiento y sus usos
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
CA2795105A1 (en) * 2010-05-05 2011-11-10 Peter Schneider Pharmaceutical formulations comprising pioglitazone and linagliptin
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
JP2018517739A (ja) * 2015-06-17 2018-07-05 ヘキサル・アクチェンゲゼルシャフト アログリプチン製剤
RU2697836C2 (ru) 2015-06-26 2019-08-21 Кореа Юнайтед Фарм. Инк. Комбинированный препарат мозаприда и рабепразола
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU8941491A (en) 1990-11-27 1992-06-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Retarded-action urapidil formulation
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6030641A (en) 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
US6660716B1 (en) 1999-06-21 2003-12-09 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
DK1741445T3 (da) 2000-01-21 2013-11-04 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CN100367960C (zh) 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
IN192749B (ko) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
PL377403A1 (pl) * 2003-01-29 2006-02-06 Takeda Pharmaceutical Company Limited Sposób wytwarzania preparatu powlekanego
JP4361461B2 (ja) 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
ZA200602056B (en) 2003-10-31 2007-05-30 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
SI1715893T1 (sl) 2004-01-20 2009-12-31 Novartis Pharma Ag Direktna kompresijska formulacija in postopek
CN102127053A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
CA2581298A1 (en) 2004-10-25 2006-05-04 Novartis Ag Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CN102908350B (zh) 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
RU2438671C2 (ru) 2005-12-28 2012-01-10 Такеда Фармасьютикал Компани Лимитед Терапевтическое средство против диабета

Also Published As

Publication number Publication date
IL200108A0 (en) 2010-04-15
RS51592B (en) 2011-08-31
ME01239B (me) 2013-06-20
DK2107905T3 (da) 2011-01-31
CY1111264T1 (el) 2015-08-05
CR10992A (es) 2009-09-16
BRPI0807453A2 (pt) 2014-05-20
PT2107905E (pt) 2010-12-17
IL200108A (en) 2012-02-29
EP2107905A1 (en) 2009-10-14
ATE488227T1 (de) 2010-12-15
JP5284968B2 (ja) 2013-09-11
UA95828C2 (ru) 2011-09-12
PL2107905T3 (pl) 2011-04-29
JP2010517937A (ja) 2010-05-27
KR101486091B1 (ko) 2015-01-23
NZ579008A (en) 2012-02-24
HRP20110094T1 (hr) 2011-03-31
CL2008000279A1 (es) 2008-08-18
DOP2009000195A (es) 2009-08-31
GEP20125410B (en) 2012-02-27
MX2009008100A (es) 2009-08-07
CA2677201A1 (en) 2008-08-07
BRPI0807453B1 (pt) 2021-01-05
AU2008211981A1 (en) 2008-08-07
CN101646420A (zh) 2010-02-10
EA015180B1 (ru) 2011-06-30
TW200836775A (en) 2008-09-16
US8637079B2 (en) 2014-01-28
ES2354397T3 (es) 2011-03-14
SI2107905T1 (sl) 2011-03-31
HRP20110094T8 (en) 2011-07-31
MY147596A (en) 2012-12-31
JO2650B1 (en) 2012-06-17
EA200970726A1 (ru) 2010-02-26
CA2677201C (en) 2015-11-17
ECSP099608A (es) 2009-09-29
KR20090109115A (ko) 2009-10-19
AU2008211981B2 (en) 2012-09-20
WO2008093882A1 (en) 2008-08-07
DE602008003522D1 (de) 2010-12-30
MA31169B1 (fr) 2010-02-01
TW201350143A (zh) 2013-12-16
EP2107905B1 (en) 2010-11-17
TWI453041B (zh) 2014-09-21
US20100092551A1 (en) 2010-04-15
CN101646420B (zh) 2012-11-07
TN2009000317A1 (en) 2010-12-31
PE20081663A1 (es) 2008-12-25
BRPI0807453B8 (pt) 2021-05-25
AR065097A1 (es) 2009-05-13
ZA200905621B (en) 2010-10-27

Similar Documents

Publication Publication Date Title
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
HK1256805A1 (zh) 藥物組合物和其給藥
ZA201000831B (en) Solid preparation comprising alogliptin and metformin hydrochloride
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2124550A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND THEIR USE
HK1129566A1 (en) Oral preparation comprising pioglitazone
HK1151791A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
GB0611115D0 (en) Compounds and their use
HK1161720A1 (en) Dihydroetorphines and their preparation
EP2322505A4 (en) 1-ADAMANTYLAZETIDIN-2-ON DERIVATIVE, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION THEREWITH
GB0714500D0 (en) composition and treatment
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
IL207414A0 (en) Siva 3, its preparation and use
ZA201008384B (en) Lasalocid compositions and methods
GB0821348D0 (en) Compounds and preparation methods
EP2110384A4 (en) HEPATOPOIETIN AND USE THEREOF
GB0813473D0 (en) Antimicrobial preparations and methods
GB0708305D0 (en) Plug and play unit
HU0800405D0 (en) Ewnvironment-friendly biocidis and use thereof
GB0603374D0 (en) Compounds and their use
GB0603376D0 (en) Compounds and their use
GB0603378D0 (en) Compounds and their use
GB0608846D0 (en) Compounds and their use
GB0610888D0 (en) Compounds and their use